Answers are grounded in this paper and cite their sources.
Although no statistically significant OS benefit was observed, the HR numerically favored olaparib, which also conferred clinically meaningful benefits including increased time off chemotherapy and long-term survival in a subset of patients.
No takes yet. Share an insight, caveat, or question.
Kindler et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: